The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Open accessAbstract
Background Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.Methods We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain. Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed). We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 week cycles of standard intravenous chemotherapy of cisplatin 75 mg/m(2) on day 1 plus docetaxel (75 mg/m(2) on day 1) or gemcitabine (1250 mg/m(2) on days 1 and 8). Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We assessed safety in all patients who received study drug (≥ 1 dose). This study is registered with ClinicalTrials.gov, number NCT00446225.Findings Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled. One patient received treatment before randomisation and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive standard chemotherapy. The preplanned interim analysis showed that the study met its primary endpoint; enrolment was halted, and full evaluation of the results was recommended. At data cutoff (Jan 26, 2011), median PFS was 9·7 months (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 months (4·5-5·8) in the standard chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p < 0·0001). Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anaemia (one [1%] vs three [4%]), and increased amino-transferase concentrations (two [2%] vs 0). Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy. One patient in the erlotinib group and two in the standard chemotherapy group died from treatment-related causes.Interpretation Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-positive patients with EGFR tyrosine-kinase inhibitors.Funding Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Temática de Investigacion Cooperativa en Cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“have shown improved efficacy and tolerability compared with chemotherapy in numerous phase III trials”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [32]
In the citing paper
“In clinical trials, the incidence of all-grade liver injury due to different smallmolecule targeted drugs such as tyrosine kinase inhibitors is reportedly 5-55% [144-149].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [147]
In the citing paper
“Afterwards, studies revealed that the reduced sensitivity to gefitinib or erlotinib in NSCLC was linked to EGFR-specific activating mutations.112–116”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [116]
In the citing paper
“The third-generation EGFR-TKIs include the WZ4002, CO-1686, AZD9291 and HM61713 inhibitors, which have demonstrated tumour responses in >50% of patients with the EGFR T790M mutation.8–12”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Eight randomised controlled phase III trials (table 1) have demonstrated that first-generation or second-generation EGFR-TKIs represent the best first-line treatment option in patients with advanced NSCLC whose tumours harbour EGFR mutations, when compared with chemotherapy, because they significantly improved the RR and progression-free survival (PFS).4–11”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [9]
In the citing paper
“Unfortunately, whilst patients with EGFRm+ tumors typically show good initial responses to first generation TKIs, most patients who respond to therapy ultimately develop disease progression after about 9-14 months of treatment (7-11).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [10]
In the citing paper
“Across clinical trials of first-line targeted therapy for oncogene-addicted subgroups of NSCLC, rates of objective response [G] typically range between 50% and 83% and complete responses [G] are rare; in addition, some patients exhibit de novo resistance16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [18]
In the citing paper
“The magnitude of the improvement in progression-free survival observed in the current study is similar to that observed in studies of EGFR-mutation-positive tumors treated with firstline EGFR tyrosine kinase inhibitors.[24][25][26]”
From First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer (2014) · cites this paper as [25]
In the citing paper
“EGFR exon 19 deletions and EGFR exon 21 L858R represent the vast majority of EGFR activating mutations, and are exquisitely sensitive to approved EGFR TKIs such as erlotinib, gefitinib, and afatinib”
From Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC (2018) · cites this paper as [2]
In the citing paper
“acquired resistance develops after a median of 9 to 13 months [2][3][4]”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [3]
In the citing paper
“Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4–6.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“Patients with classical EGFR mutations (L858R or exon 19 deletions (Ex19del)) show marked improvements in clinical outcomes when treated with first-, second- or third-generation tyrosine kinase inhibitors (TKIs)4–6,11.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [4]
In the citing paper
“One potential limitation of the current diagnostic approach of testing only for common exon 19 and 21 mutations, as was done in the EURTAC or OPTIMAL studies, 4,5 is that such an approach might miss identifying a number of patients who could have some benefit from EGFR TKI treatment.”
From Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations (2016) · cites this paper as [5]
In the citing paper
“a strikingly long survival compared to median OS of 19–28 months with first- or second-generation EGFR TKIs[17–19].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [19]
In the citing paper
“Several randomized clinical trials have demonstrated that EGFR TKIs are more effective, as measured by response rate (RR) and progression free survival (PFS), than chemotherapy when used as initial systemic treatment for advanced EGFR mutant NSCLC (1, 4–9).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective clinical therapies for EGFR mutant advanced non small cell lung cancer (NSCLC) patients (1–4).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [4]
In the citing paper
“The extension of approval of Erlotinib for patients harboring EGFR mutations, in addition to the previous indication for unselected patients with NSCLC after at least one chemotherapeutic line, was obtained after the publication of two large phase III trials conducted in Asia [65] and Europe [66], providing the definitive demonstration of superiority of an EGFR TKI over standard first-line”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [66]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [8]
In the citing paper
“Despite high tumor response rates with first-line EGFR-TKIs, disease progresses in a majority of patients after 9 to 13 months of treatment.5–12”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [7]
In the citing paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [3]
In the citing paper
“Several studies have consistently demonstrated that the EGFR TKIs (gefitinib, erlotinib and afatinib) produce higher RRs, longer PFS and improve QoL compared with standard platinum-based doublet chemotherapy in patients with good PS (PS 0-2), whose tumour harbours an activating (sensitising) EGFR mutation [105-112].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [112]
In the citing paper
“In one small study, there was a PFS benefit with erlotinib (9.7 v 5.2 months; HR, 0.37; 95% CI, 0.25 to 0.54; P < .001); OS had not been reached by the time of publication.29”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“Since the publication of the ASCO 2009 guideline and the ASCO EGFR provisional clinical opinion,59 results from seven trials of first-line EGFR TKIs for patients with EGFR mutations have been published.11,13,29,31,34,36,40”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [29]
In the citing paper
“It is now well established that lung cancers harboring these EGFR mutations are highly responsive to single-agent EGFR inhibitors with RECIST response rates of ~55%–75% (Mok et al., 2009; Rosell et al., 2012; Sequist et al., 2013b).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Rosell et al., 2012
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Self-citation
Research works printed but not linked: 1
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) version 13.0 (accessed Aug 2, 2010).
Cited by
Sorted by citations
Items 801–900 of 1,020
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
Nanjo, S., Wu, W., Karachaliou, N., Blakely, C. M., Suzuki, J., Chou, Y., Ali, S. M., Kerr, D. L., Olivas, V. R., Shue, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145099 · Cited by 70
Self-citationThe role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer
Ciardiello, F., Hirsch, F. R., Pirker, R., Felip, E., Valencia, C., & Smit, E. F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102664 · Cited by 72
Self-citationHsu, J., Huang, M., Chen, C., Liu, G., Liu, T., Chong, I., Chou, S., & Yang, C. (2014) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000116 · Cited by 70
Gridelli, C., Balducci, L., Ciardiello, F., Maïo, M. D., Felip, E., Langer, C. J., Lilenbaum, R., Perrone, F., Senan, S., & de Marinis, F. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.02.006 · Cited by 70
Self-citationInnovative Clinical Trials: The LUNG‐MAP Study
Steuer, C., Papadimitrakopoulou, V., Herbst, R. S., Redman, M. W., Hirsch, F., Mack, P. C., Ramalingam, S., & Gandara, D. R. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.88 · Cited by 70
Chen, C., Statt, S. N., Chiu, C.-L., Thai, P., Arif, M., Adler, K. B., & Wu, R. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1505oc · Cited by 70
Worldwide Overview of the Current Status of Lung Cancer Diagnosis and Treatment
Bunn, P. A. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0295-sa · Cited by 70
Using biomaterials to rewire the process of wound repair
Stejskalová, A., & Almquist, B. D. (2017) · Biomaterials Science · doi:10.1039/c7bm00295e · Cited by 71
Pi, C., Xu, C., Zhang, M., Peng, X., Wei, X., Gao, X., Yan, H., & Zhou, Q. H. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12651 · Cited by 70
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
Georgieva, M., Lima, J. P., Aguiar, P. N., Lopes, G. D. L., Jr., & Haaland, B. A. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.08.018 · Cited by 70
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 69
Lopes, G. L., Vattimo, E. F. D. Q., & de Castro, G. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000004531 · Cited by 69
Abate, R. E., Frezzetti, D., Maiello, M. R., Gallo, M., Camerlingo, R., Luca, A. D., Cecio, R. D., Morabito, A., & Normanno, N. (2020) · Cancers · doi:10.3390/cancers12123804 · Cited by 69
Rotow, J. K., Lee, J., Madison, R. W., Oxnard, G. R., Janne, P. A., & Schrock, A. B. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.1453 · Cited by 69
Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer
Yano, T. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.1048 · Cited by 69
Epidermal Growth Factor Receptor Inhibitors: Coming of Age
Mahipal, A., Kothari, N., & Gupta, S. (2014) · Cancer Control · doi:10.1177/107327481402100111 · Cited by 69
Park, J. H., Choi, Y. J., Kim, S. Y., Lee, J., Sung, K. J., Park, S., Kim, W. S., Song, J. S., Choi, C., Sung, Y. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8013 · Cited by 69
Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury
Heery, C. R., Palena, C., McMahon, S., Donahue, R. N., Lepone, L. M., Grenga, I., Dirmeier, U., Cordes, L. M., Marte, J., Dahut, W. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1087 · Cited by 69
Chen, M., Xu, Y., Zhao, J., Zhong, W., Zhang, L., Bi, Y., & Wang, M. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.023 · Cited by 69
Kashima, J., Kitadai, R., & Okuma, Y. (2019) · Cancers · doi:10.3390/cancers11050599 · Cited by 69
Sjin, R. T. T., Lee, K., Walter, A. O., Dubrovskiy, A., Sheets, M. P., Martin, T. S., Labenski, M., Zhu, Z., Tester, R. W., Karp, R., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0966 · Cited by 68
Eide, I. J. Z., Helland, Å., Ekman, S., Mellemgaard, A., Hansen, K. H., Cicėnas, S., Koivunen, J. P., Grønberg, B. H., & Brustugun, O. T. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.009 · Cited by 68
Mu, Y., Hao, X., Xing, P., Hu, X., Wang, Y., Li, T., Zhang, J., Xu, Z., & Li, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03239-1 · Cited by 68
Yang, Z., Xu, J., Li, L., Li, R., Wang, Y., Tian, Y., Guo, W., Wang, Z., Tan, F., Ying, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18702-3 · Cited by 68
Lam, T., Tsang, K. C., Choi, C., Lee, V. H.-F., Lam, K. O., Chiang, C., So, T. H., Chan, W., Nyaw, S. F., Lim, F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.004 · Cited by 68
Lorenzi, M., Ferro, A., Cecere, F. L., Scattolin, D., Conte, A. D., Follador, A., Pilotto, S., Polo, V., Santarpía, M., Chiari, R., et al. (2021) · The Oncologist · doi:10.1002/onco.13951 · Cited by 68
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
Muthusamy, B., Patil, P. D., & Pennell, N. A. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7021 · Cited by 69
Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer
Gower, A., Wang, Y., & Giaccone, G. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1165-y · Cited by 68
The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian population
Skov, B. G., Høgdall, E. V. S., Clementsen, P. F., Krasnik, M., Larsen, K. R., Sørensen, J. B., Skov, T., & Mellemgaard, A. (2014) · Apmis · doi:10.1111/apm.12328 · Cited by 68
Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies
Meador, C. B., Micheel, C., Levy, M. A., Lovly, C. M., Horn, L., Warner, J. L., Johnson, D. B., Zhao, Z., Anderson, I. A., Sosman, J. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1591 · Cited by 68
Molecular Profiling in Non–Small Cell Lung Cancer: A Step Toward Personalized Medicine
Raparia, K., Villa, C., DeCamp, M. M., Patel, J. D., & Mehta, M. P. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0287-ra · Cited by 68
New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice
Forde, P. M., Kelly, R. J., & Brahmer, J. R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0731 · Cited by 68
Becht, É., Giraldo, N. A., Beuselinck, B., Job, S., Marisa, L., Vano, Y. A., Oudard, S. M., Zucman‐Rossi, J., Laurent‐Puig, P., Sautès‐Fridman, C., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1049804 · Cited by 68
Reguart, N., Teixidó, C., Giménez-Capitán, A. A., Paré, L., Galván, P., Viteri, S., Rodríguez, S., Peg, V., Aldeguer, E., Viñolas, N., et al. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.265314 · Cited by 68
Self-citationBollinger, M. K., Agnew, A. S., & Mascara, G. P. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217712401 · Cited by 69
Yoda, S., Dagogo‐Jack, I., & Hata, A. N. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.007 · Cited by 68
microRNA: The Impact on Cancer Stemness and Therapeutic Resistance
Jiao, X., Qian, X., Wu, L., Li, B., Wang, Y., Kong, X., & Xiong, L. (2019) · Cells · doi:10.3390/cells9010008 · Cited by 68
Prognostic value of EGFR 19‑del and 21‑L858R mutations in patients with non‑small cell lung cancer
Hong, W., Wu, Q., Zhang, J., & Zhou, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10715 · Cited by 67
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 67
Current Bioinformatics Tools in Precision Oncology
Wolde, T., Bhardwaj, V., & Pandey, V. (2025) · MedComm · doi:10.1002/mco2.70243 · Cited by 67
FGFR as potential target in the treatment of squamous non small cell lung cancer
Tiseo, M., Gelsomino, F., Alfieri, R. R., Cavazzoni, A., Bozzetti, C., Giorgi, A. D., Petronini, P. G., & Ardizzoni, A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.011 · Cited by 67
Li, X., Cai, W., Yang, G., Su, C., Ren, S., Zhao, C., Hu, R., Chen, X., Gao, G., Guo, Z., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.006 · Cited by 67
Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66
Zhou, Q. H., Cheng, Y., Yang, J., Zhao, M., Zhang, L., Zhang, X.-C., Chen, Z., Yan, H., Song, Y., Chen, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu463 · Cited by 66
Elamin, Y. Y., Gomez, D. R., Antonoff, M. B., Robichaux, J. P., Tran, H. T., Shorter, M. K., Bohac, J. M., Negrao, M. V., Le, X., Rinsurogkawong, W., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.015 · Cited by 66
KRAS mutations testing in non-small cell lung cancer: the role of Liquid biopsy in the basal setting
Nacchio, M., Sgariglia, R., Gristina, V., Pisapia, P., Pepe, F., Luca, C. D., Migliatico, I., Clery, E., Greco, L., Vigliar, E., et al. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.01.19 · Cited by 66
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Pujol, J.-L., Pirker, R., Lynch, T. J., Butts, C. A., Rosell, R., Shepherd, F. A., Vansteenkiste, J., O'Byrne, K. J., de Blas, B., Heighway, J., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.006 · Cited by 66
Self-citationCancer stem cells, microRNAs, and therapeutic strategies including natural products
Vira, D., Basak, S. K., Veena, M. S., Wang, M. B., Batra, R. K., & Srivatsan, E. S. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9382-8 · Cited by 66
Cretella, D., Saccani, F., Quaini, F., Frati, C., Lagrasta, C. A., Bonelli, M. A., Caffarra, C., Cavazzoni, A., Fumarola, C., Galetti, M., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-143 · Cited by 66
Alopecia in patients treated with molecularly targeted anticancer therapies
Belum, V. R., Marulanda, K., Ensslin, C., Gorcey, L., Parikh, T., Wu, S., BUSAM, K. J., Gerber, P. A., & Lacouture, M. E. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv390 · Cited by 66
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Dulaney, C. R., Marcrom, S., Stanley, J. A., & Yang, E. S.-H. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.01.007 · Cited by 66
Chan, O. S. H., Lee, V. H.-F., Mok, T. S. K., Mo, F. K. F., Chang, A. T. Y., & Yeung, R. M. W. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.04.035 · Cited by 66
Zhong, W., Zhou, Q. H., & Wu, Y.-L. L. C. (2017) · Oncotarget · doi:10.18632/oncotarget.20311 · Cited by 66
Fan, Y., Zhu, X., Xu, Y., Lu, X., Xu, Y., Wang, M., Xu, H., Ding, J., Ye, X., Fang, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1582 · Cited by 66
Li, T., Ding, Z., Zheng, Y., & Wang, W. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.102 · Cited by 66
MET targeting: time for a rematch
Koch, J. P., Aebersold, D. M., Zimmer, Y., & Medová, M. (2020) · Oncogene · doi:10.1038/s41388-020-1193-8 · Cited by 66
Krawczyk, P., Kowalski, D. M., Ramlau, R., Kalinka-Warzocha, E., Winiarczyk, K., Stencel, K., Powrózek, T., Reszka, K., Wojas-Krawczyk, K., Bryl, M., et al. (2017) · Oncology Letters · doi:10.3892/ol.2017.5980 · Cited by 65
Ting, J., Tien Ho, P., Xiang, P., Sugay, A., Abdel-Sattar, M., & Wilson, L. (2015) · Value in Health · doi:10.1016/j.jval.2015.04.008 · Cited by 65
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Gao, S. P., Chang, Q., Mao, N., Daly, L., VOGEL, R. M., Chan, T., Liu, S. H., Bournazou, E., Schori, E., Zhang, H., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac8460 · Cited by 65
Goldberg, S. B., Redman, M. W., Lilenbaum, R., Politi, K. A., Stinchcombe, T. E., Horn, L., Chen, E. H., Mashru, S. H., Gettinger, S. N., Melnick, M. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01149 · Cited by 65
Platinum drugs and DNA repair mechanisms in lung cancer.
Bonanno, L., Favaretto, A. G., & Rosell, R. (2014) · PubMed · Cited by 65
Self-citationTakeda, M., Okamoto, I., & Nakagawa, K. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000053 · Cited by 65
Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer
Schneider, M. A., Granzow, M., Warth, A., Schnabel, P. A., Thomas, M., Herth, F. J. F., Dienemann, H., Muley, T., & Meister, M. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2464 · Cited by 65
Ninomiya, T., Takigawa, N., Ichihara, E., Ochi, N., Murakami, T., Honda, Y., Kubo, T., Minami, D., Kudo, K., Tanimoto, M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0885 · Cited by 65
Karachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 65
Self-citationSullivan, I., & Planchard, D. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816670498 · Cited by 65
Tomasello, C., Baldessari, C., Napolitano, M., Orsi, G., Grizzi, G., Bertolini, F., Barbieri, F., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.013 · Cited by 65
Helman, E., Nguyen, M., Karlovich, C., Despain, D., Choquette, A. K., Spira, A. I., Yu, H. A., Camidge, D. R., Harding, T. C., Lanman, R. B., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.07.008 · Cited by 65
Lee, Y., Lee, G. K., Lee, Y., Zhang, W., Hwang, J., Nam, B., Kim, S. H., Joo‐Hang, K. I. M., Yun, T., Han, J., et al. (2014) · Cancer · doi:10.1002/cncr.28711 · Cited by 64
Scott, J. A., Lennerz, J. K., Johnson, M. L., Gordan, L., Dumanois, R. H., Quagliata, L., Ritterhouse, L. L., Cappuzzo, F., Wang, B., Xue, M., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00611 · Cited by 64
Lee, J. G., & Wu, R. (2015) · Neoplasia · doi:10.1016/j.neo.2014.12.008 · Cited by 64
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
Casadevall, D., Gimeno, J., Clavé, S., Taus, Á., Pijuán, L., Arumí, M., Lorenzo, M., Menéndez, S., Cañadas, I., Albanell, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3976 · Cited by 64
Lim, C. H., Sung, M., Shepherd, F. A., Nouriany, N., Sawczak, M., Paul, T., Perera-Low, N., Foster, A., Zawisza, D., Feld, R. D., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.006 · Cited by 64
Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR
Engel, J., Becker, C., Lategahn, J., Keul, M., Ketzer, J., Mühlenberg, T., Kollipara, L., Schultz‐Fademrecht, C., Zahedi, R. P., Bauer, S., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201605011 · Cited by 64
Zhang, H. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s119162 · Cited by 64
Addressing the challenges of applying precision oncology
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0032-z · Cited by 65
der Welle, C. M. C., Peters, B. J. M., Schramel, F. M. N. H., Klungel, O. H., Groen, H. J. M., & van de Garde, E. M. W. (2018) · European Respiratory Journal · doi:10.1183/13993003.01100-2018 · Cited by 64
Cyclodextrin-based nanosponges as promising carriers for active agents
Allahyari, S., Trotta, F., Valizadeh, H., Jelvehgari, M., & Zakeri‐Milani, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1591365 · Cited by 64
Noronha, V., Rajendra, A., Joshi, A., Patil, V., Menon, N. N., & Prabhash, K. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_51_19 · Cited by 64
Zhao, Y., Cheng, B., Chen, Z., Li, J., Liang, H., Chen, Y., Zhu, F., Li, C., Xu, K., Xiong, S., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103305 · Cited by 65
Lin, Y., Chen, J., Liao, W., Ho, C., Hsu, C., Yang, C., Chen, K., Lee, J., Lin, Z., Shih, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32025 · Cited by 63
Romaniello, D., Marrocco, I., Nataraj, N. B., Ferrer, I., Garcia, D. D., Vaknin, I., Oren, R., Lindzen, M., Ghosh, S., Kreitman, M., et al. (2020) · Cancers · doi:10.3390/cancers12092394 · Cited by 63
Self-citationAgazzi, G. M., Ravanelli, M., Roca, E., Medicina, D., Balzarini, P., Pessina, C., Vermi, W., Berruti, A., Maroldi, R., & Farina, D. (2021) · La radiologia medica · doi:10.1007/s11547-020-01323-7 · Cited by 63
Sacco, J. J., Kenyani, J., Butt, Z., Carter, R., Chew, H. Y., Cheeseman, L. P., Darling, S., Denny, M., Urbé, S., Clague, M. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3765 · Cited by 63
Zhao, N., Zhang, X., Yan, H., Yang, J., & Wu, Y.-L. L. C. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.026 · Cited by 63
HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches.
Garrido-Castro, A. C., & Felip, E. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.02.02 · Cited by 63
Self-citationTartarone, A., Lazzari, C., Lerose, R., Conteduca, V., Improta, G., Zupa, A., Bulotta, A., Aieta, M., & Gregorc, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.05.020 · Cited by 63
Gillis, N., Patel, J. N., & Innocenti, F. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.214 · Cited by 63
Ten Years of Progress in Non–Small Cell Lung Cancer
Ettinger, D. S. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0029 · Cited by 63
Campo, M. J., Al-Halabi, H., Khandekar, M. J., Shaw, A. T., Sequist, L. V. D., & Willers, H. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0508 · Cited by 65
MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis
Mizuno, K., Mataki, H., Seki, N., Kumamoto, T., Kamikawaji, K., & Inoue, H. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.98 · Cited by 63
Lee, Y., Lee, K. H., Lee, G. K., Lee, S.-H., Lim, K. Y., Joo, J., Go, Y., Lee, J. S., & Han, J. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.546 · Cited by 63
Lee, C., Kim, S., Lee, J. E., Lee, J. E., Kim, S.-M., Yang, I. S., Kim, H. R., Lee, J. H., Kim, S., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.09.005 · Cited by 63
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park, S., Shim, J., Lee, B., Cho, I., Park, W., Kim, Y., Lee, S., Choi, Y., Han, J., Ahn, J. S., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.024 · Cited by 63
Li, X.-M., Li, W., Lin, J., Yan, H., Tu, H., Chen, H., Wang, B.-C., Wang, Z., Zhou, Q. H., Zhang, X., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.001 · Cited by 63
Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC
Zeng, H., Castillo-Cabrera, J., Manser, M., Lu, B., Yang, Z., Strande, V., Begue, D., Zamponi, R., Qiu, S., Sigoillot, F., et al. (2019) · eLife · doi:10.7554/elife.50223 · Cited by 57
Steuer, C. E., Khuri, F. R., & Ramalingam, S. S. (2014) · Cancer · doi:10.1002/cncr.29139 · Cited by 62
Review of the current targeted therapies for non-small-cell lung cancer
Nguyen, K.-S. H. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.576 · Cited by 62
Chen, X., Liu, Y., Røe, O. D., Qian, Y., Guo, R., Zhu, L., Yin, Y., & Shu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059314 · Cited by 62
Metadata
- Authors
- Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., Porta, R., Cobo, M., Garrido, P., Longo, F., Moran, T., Insa, A., De Marinis, F., Corre, R., Bover, I., Illiano, A., Dansin, E., de Castro, J., Milella, M., Reguart, N., Altavilla, G., Jimenez, U., Provencio, M., Moreno, M. A., Terrasa, J., Muñoz-Langa, J., Valdivia, J., Isla, D., Domine, M., Molinier, O., Mazieres, J., Baize, N., Garcia-Campelo, R., Robinet, G., Rodriguez-Abreu, D., Lopez-Vivanco, G., Gebbia, V., Ferrera-Delgado, L., Bombaron, P., Bernabe, R., Bearz, A., Artal, A., Cortesi, E., Rolfo, C., Sanchez-Ronco, M., Drozdowskyj, A., Queralt, C., de Aguirre, I., Ramirez, J. L., Sanchez, J. J., Molina, M. A., Taron, M., & Paz-Ares, L.
- Affiliations
- Institut Català d'Oncologia (ES)
- Centre François Baclesse (FR)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Ramón y Cajal (ES)
- Policlinico Umberto I (IT)
- Hospital Clínico Universitario de Valencia (ES)
- Hôpital Pontchaillou (FR)
- Hospital Son Llatzer (ES)
- Azienda Ospedaliera Universitaria Policlinico "G. Martino" (IT)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hospital Universitario Son Dureta (ES)
- Hospital Universitario Virgen de las Nieves (ES)
- Hospital Clínico Universitario Lozano Blesa (ES)
- Centre Hospitalier du Mans (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- La Maddalena (IT)
- Hospital Universitario Nuestra Señora de Candelaria (ES)
- Centre Hospitalier de Mulhouse (FR)
- Centro di Riferimento Oncologico (IT)
- Hospital Universitario Miguel Servet (ES)
- Sapienza University of Rome (IT)
- Clinica Rotger (ES)
- Pivotal (Spain) (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Corresponding author
- Rosell, Rafael
- ORCID
- Rosell, Rafael
- Carcereny, Enric
- Gervais, Radj
- Felip, Enriqueta
- Cobo, Manuel
- Garrido, Pilar
- Longo, Flavia
- Insa, Amelia
- Corre, Romain
- Altavilla, Giuseppe
- Provencio, Mariano
- Valdivia, Javier
- Isla, Dolores
- Molinier, Olivier
- Gebbia, Vittorio
- Bearz, Alessandra
- Artal, Angel
- Cortesi, Enrico
- Rolfo, Christian
- Queralt, Cristina
- Paz-Ares, Luis
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 13
- Issue
- 3
- Pages
- 239-246
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2111662961
- Cited by
- 5,489
- References
- 23
- Citations by year
- 2026: 92 · 2025: 169 · 2024: 216 · 2023: 269 · 2022: 367 · 2021: 422 · 2020: 441 · 2019: 440 · 2018: 498 · 2017: 534 · 2016: 509 · 2015: 537 · 2014: 448 · 2013: 401 · 2012: 138
- FWCI
- 392.78
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- erlotinib, EGFR-mutant non-small cell lung cancer, first-line therapy, exon 19 deletion, L858R mutation, cisplatin, docetaxel, gemcitabine, carboplatin, progression-free survival, targeted therapy, European patients, drug safety, adverse events, treatment discontinuation, EGFR tyrosine kinase inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Docetaxel, Gemcitabine, Administration, Oral, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Drug Administration Schedule, Europe, Exons, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Prospective Studies, Quinazolines, Time Factors, Chi-Square Distribution, Proportional Hazards Models, Carboplatin, Treatment Outcome, Disease-Free Survival, Patient Selection, Taxoids, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Precision Medicine, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
